

# Anti-IL-17R $\alpha$ (Brodalumab), Human IgG2 Antibody

06/20

---

**CATALOG NO.:** A2155-100 (100  $\mu$ g)
 

---

**BACKGROUND DESCRIPTION:** The research-grade biosimilar is a recombinant, fully human IgG2 kappa monoclonal antibody that binds with a high affinity to the Interleukin-17 receptor  $\alpha$  (IL-17R $\alpha$ ). IL-17R is a type I membrane glycoprotein that is ubiquitously expressed on cell surfaces and binds IL17 $\alpha$  with low affinity. IL17 $\alpha$  plays an important role in the pathogenesis of inflammatory and autoimmune diseases such as rheumatoid arthritis. The antibody binds to the IL-17R $\alpha$  and inhibits IL-17 induced release of pro-inflammatory cytokines and chemokines such as NF- $\kappa$ B, IL-6, IL-8, COX-2, MMPs, and GM-CSF. The original drug received approval from the FDA to treat moderate-to-severe psoriasis.

**ALTERNATE NAMES:** AMG827, KHK4827, AMG 827, AMG-827, KHK-4827, KHK4827, IL17RA, CD217

**ANTIBODY TYPE:** Monoclonal

**CONCENTRATION:** 1 mg/ml

**HOST/ISOTYPE:** Recombinant / IgG2, kappa

**SOURCE:** CHO cells

**IMMUNOGEN:** Human IL-17R $\alpha$

**PURIFICATION:** Protein A purified

**FORM:** Liquid

**FORMULATION:** In PBS, pH 7.5

**SPECIES REACTIVITY:** Human

**STORAGE CONDITIONS:** Store at -80°C

**This information is only intended as a guide. The optimal dilutions must be determined by the user**

**RELATED PRODUCTS:**

Anti-IL-6 (Siltuximab), Chimeric Antibody (A2143)  
 Anti-IL-12 $\beta$  (Ustekinumab), Human IgG1 Antibody (A2137)  
 Anti-IL-23 $\alpha$  (Guselkumab), Human IgG1 Antibody (A2147)  
 Anti-IL-17 $\alpha$  (Ixekizumab), Humanized Antibody (A2149)  
 Anti-IL-1 $\beta$  (Canakinumab), Human IgG1 Antibody (A2144)

**FOR RESEARCH USE ONLY! Not to be used on humans.**